Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics

Medical and Pediatric Oncology

Volumn 26, Issue 2, 1996, Pages 85-89

  Berkovitch, Matitiahu ^a   Matsui, Doreen ^a   Zipursky, Alvin ^a   Blanchette, Victor S ^a   Verjee, Zul ^a   Giesbrecht, Esther ^a   Saunders, Earl F ^a   Evans, William E ^b   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

6 mercaptopurine; acute lymphocytic leukemia; hepatotoxicity

Indexed keywords

MERCAPTOPURINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHILD; CHILDHOOD LEUKEMIA; CHOLESTASIS; CLINICAL FEATURE; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MALE; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; CHOLESTASIS, INTRAHEPATIC; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIVER; MALE;

EID: 0030050184     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199602)26:2<85::AID-MPO3>3.0.CO;2-Q     Document Type: Article

References (14)

1. Clark PA, Hsia YE, Huntsman RG: Toxic complications of treatment with 6-mercaptopurine: Two cases with hepatic necrosis and intestinal ulceration. Br Med J 1:393-395, 1960.
2. Shorey J, Schenker S, Suki WN, Combes B: Hepatotoxicity of mercaptopurine. Arch Intern Med 122:54-58, 1968.
3. Harb JM, Werlin SL, Camitta BM, Oechler H, Kamen BA, Blank EL: Hepatic ultrastructure in leukemic children treated with methotrexate and 6-mercaptopurine. Am J Pediatr Hemat Oncol 5:323-331, 1983.
4. Einhorn M, Davidson I: Hepatotoxicity of mercaptopurine. JAMA 188:802-806, 1964.
5. Zimm S, Reamson G, Murphy RF, Poplack DG: Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 46:1495-1498, 1986.
6. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner BC, Poplack DG: Variable bioavailability of oral mercaptopurine: Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005-1009, 1983.
7. Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M: Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 40:604-609, 1986.
8. Whalen CE, Tamary H, Greenberg M, Zipursky A, Soldin S: Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography. Ther Drug Monit 7:315-320, 1985.
9. Lennard L: Assay of 6-thiomosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine in human red blood cells. J Chromatogr 423:169-178, 1987.
10. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 85:323-333, 1978.
11. Lennard L, Rees CA, Lilleyman JS, Maddocks JL: Childhood leukemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16:359-363, 1983.
12. Szumlanski CL, Scott MC, Weinshilboum RM: Thiopurine methyltransferase pharmacokinetics. Human liver enzyme activity. Clin Pharmacol Ther 143:134, 1988.
13. Evans WE, Horner M, Chu YQ, Kalurinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985-989, 1991.
14. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 336:225-229, 1990.